Article Per Year (5 Year)
p-Index From 2021 - 2026
0.408
P-Index
This Author published in this journals
All Journal Sciences and Clinical Pharmacy Research Journal
Gunasari, Lala
Unknown Affiliation
Medicine & Pharmacology

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
From Drug of Choice to Publich Health Tool: A Narrative Review of Ivermectin for Strongyloidiasis Control Nurmansyah, Dian; Gunasari, Lala; Puspawati
Sciences and Clinical Pharmacy Research Journal Vol. 3 No. 1 (2026): April
Publisher : Indonesian Journal Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.47134/scpr.v3i1.5600

Abstract

This narrative review analyses the gap between its clinical supremacy and inadequate public health translation. A structured literature search (2020-2025) using MeSH terms including Ivermectin, Strongyloides stercoralis, and soil-transmitted helminths was conducted via ScienceDirect and Google Scholar. The retrieved evidence synthesizes ivermectin's superior therapeutic profile over albendazole and critically examines the Indonesian context, where significant underdiagnosis and missed opportunities within mass drug administration programs perpetuate transmission. Key implementation barriers spanning diagnostics, policy, and health systems are identified. To address this, the review argues for a strategic paradigm shift: ivermectin must be reenvisioned from a curative agent to a cornerstone of preventative public health. Achieving this requires definitive guideline integration, targeted preventive strategies, and multi-sectoral collaboration
Re-evaluating Albendazole-Based Preventive Chemotherapy for Soil-Transmitted Helminths in Indonesia: A Narrative Review on Efficacy, Challenges, and Future Strategies Gunasari, Lala; Nurmansyah, Dian; Triana, Dessy
Sciences and Clinical Pharmacy Research Journal Vol. 3 No. 1 (2026): April
Publisher : Indonesian Journal Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.47134/scpr.v3i1.5601

Abstract

This narrative review seeks to critically analyze the efficacy of albendazole, the cornerstone anthelmintic of the program. Relevant literature (2020-2025) was identified through a systematic search of the ScienceDirect and Google Scholar databases. While evidence confirms albendazole's effectiveness, with cure rates up to 93%, its performance is inconsistent and influenced by a confluence of factors. A critical constraint identified is the absence of robust, large-scale national surveillance data on STH prevalence and drug efficacy, hindering a comprehensive assessment of albendazole's performance within the program. The persistent burden of STH underscores a gap between program implementation and its intended public health impact. While albendazole remains essential, its variable efficacy and operational barriers necessitate a critical reassessment of the current strategy.
Co-Authors Dessy Triana Puspawati